Circadian disruption and breast cancer: An epigenetic link?

Oncotarget

Volumn 6, Issue 19, 2015, Pages 16866-16882

  Kochan, David Z ^a   Kovalchuk, Olga ^a  

^a UNIVERSITY OF LETHBRIDGE   (Canada)

Author keywords

Breast cancer; Circadian disruption (CD); Circadian rhythms; Epigenetics; Melatonin (MLT)

Indexed keywords

MELATONIN; MICRORNA; RNA INDUCED SILENCING COMPLEX; TRANSCRIPTION FACTOR ARNTL; TRANSCRIPTION FACTOR CLOCK;

ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CIRCADIAN RHYTHM; CLOCK GENE; DNA METHYLATION; EPIGENETICS; GENETIC ASSOCIATION; HUMAN; NONHUMAN; SUPRACHIASMATIC NUCLEUS; TRANSCRIPTION REGULATION; ANIMAL; BREAST TUMOR; FEMALE; GENETIC EPIGENESIS; GENETICS;

ANIMALS; BREAST NEOPLASMS; CIRCADIAN CLOCKS; CLOCK PROTEINS; EPIGENESIS, GENETIC; FEMALE; HUMANS;

EID: 84938265033     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4343     Document Type: Article

References (157)

1. IARC. World cancer factsheet. World Health Organization online database: Retrieved online. 2012.
2. American Cancer Society. Breast Cancer in Men. Cancer Facts and Figures 2015, Retrieved online. 2015.
3. Giordano SH, Cohen DS, Buzdar AU, Perkins G, Hortobagyi GN. Breast carcinoma in men: a population-based study. Cancer. 2004; 101:51-57.
4. Abeloff MD, Armitage JO, Niederhuber JE, Kastan MB, McKenna WG. Abeloff's Clinical Oncology. 2008; Churchill Livingstone: Elsevier.
5. Shackney SE, Silverman JF. Molecular evolutionary patterns in breast cancer. Advances in anatomic pathology. 2003; 10:278-290.
6. Simpson PT, Reis-Filho JS, Gale T, Lakhani SR. Molecular evolution of breast cancer. The Journal of pathology. 2005; 205:248-254.
7. Britten A, Rossier C, Taright N, Ezra P, Bourgier C. Genomic classifications and radiotherapy for breast cancer. European journal of pharmacology. 2013; 717:67-70.
8. Li Y, Meeran SM, Patel SN, Chen H, Hardy TM, Tollefsbol TO. Epigenetic reactivation of estrogen receptor-alpha (ERalpha) by genistein enhances hormonal therapy sensitivity in ERalpha-negative breast cancer. Molecular cancer. 2013; 12:9.
9. Mourits MJ, De Vries EG, Willemse PH, Ten Hoor KA, Hollema H, Van der Zee AG. Tamoxifen treatment and gynecologic side effects: a review. Obstetrics and gynecology. 2001; 97:855-866.
10. Gadducci A, Biglia N, Sismondi P, Genazzani AR. Breast cancer and sex steroids: critical review of epidemiological, experimental and clinical investigations on etiopathogenesis, chemoprevention and endocrine treatment of breast cancer. Gynecological endocrinology: the official journal of the International Society of Gynecological Endocrinology. 2005; 20:343-360.
11. Jang ER, Lim SJ, Lee ES, Jeong G, Kim TY, Bang YJ, Lee JS. The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor alpha-negative breast cancer cells to tamoxifen. Oncogene. 2004; 23:1724-1736.
12. Yang X, Phillips DL, Ferguson AT, Nelson WG, Herman JG, Davidson NE. Synergistic activation of functional (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. Cancer research. 2001; 61:7025-7029.
13. Hansen J, Stevens RG. Case-control study of shift-work and breast cancer risk in Danish nurses: impact of shift systems. European journal of cancer. 2012; 48:1722-1729.
14. Cajochen C, Frey S, Anders D, Spati J, Bues M, Pross A, Mager R, Wirz-Justice A, Stefani O. Evening exposure to a light-emitting diodes (LED)-backlit computer screen affects circadian physiology and cognitive performance. Journal of applied physiology (Bethesda, Md : 1985). 2011; 110:1432-1438.
15. Filipski E, Delaunay F, King VM, Wu MW, Claustrat B, Grechez-Cassiau A, Guettier C, Hastings MH, Francis L. Effects of chronic jet lag on tumor progression in mice. Cancer research. 2004; 64:7879-7885.
16. Gooley JJ, Chamberlain K, Smith KA, Khalsa SB, Rajaratnam SM, Van Reen E, Zeitzer JM, Czeisler CA, Lockley SW. Exposure to room light before bedtime suppresses melatonin onset and shortens melatonin duration in humans. The Journal of clinical endocrinology and metabolism. 2011; 96:E463-472.
17. Mallis MM, DeRoshia CW. Circadian rhythms, sleep, and performance in space. Aviation, space, and environmental medicine. 2005; 76:B94-107.
18. Wirz-Justice A, Bromundt V, Cajochen C. Circadian Disruption and Psychiatric Disorders: The Importance of Entrainment. Sleep Medicine Clinics. 4:273-284.
19. Flynn-Evans EE, Mucci L, Stevens RG, Lockley SW. Shiftwork and prostate-specific antigen in the National Health and Nutrition Examination Survey. Journal of the National Cancer Institute. 2013; 105:1292-1297.
20. Sigurdardottir LG, Valdimarsdottir UA, Mucci LA, Fall K, Rider JR, Schernhammer E, Czeisler CA, Launer L, Harris T, Stampfer MJ, Gudnason V, Lockley SW. Sleep disruption among older men and risk of prostate cancer. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2013; 22:872-879.
21. Vinogradova IA, Anisimov VN, Bukalev AV, Semenchenko AV, Zabezhinski MA. Circadian disruption induced by light-at-night accelerates aging and promotes tumorigenesis in rats. Aging. 2009; 1:855-865.
22. Knutsson A, Alfredsson L, Karlsson B, Akerstedt T, Fransson EI, Westerholm P, Westerlund H. Breast cancer among shift workers: results of the WOLF longitudinal cohort study. Scandinavian journal of work, environment & health. 2013; 39:170-177.
23. Demers PA, Wong I, McLeod C. The prevelance of shift work in Canada. the Scientific Symposium on the Health Effect of Shift Work. Toronto, ON: April 2010.
24. Rabstein S, Harth V, Pesch B, Pallapies D, Lotz A, Justenhoven C, Baisch C, Schiffermann M, Haas S, Fischer HP, Heinze E, Pierl C, Brauch H, Hamann U, Ko Y, Bruning T, et al. Night work and breast cancer estrogen receptor status-results from the German GENICA study. Scandinavian journal of work, environment & health. 2013; 39:448-455.
25. Moore RY. Organization and function of a central nervous system circadian oscillator: the suprachiasmatic hypothalamic nucleus. Federation proceedings. 1983; 42:2783-2789.
26. Zelinski EL, Deibel SH, McDonald RJ. The trouble with circadian clock dysfunction: multiple deleterious effects on the brain and body. Neuroscience and biobehavioral reviews. 2014; 40:80-101.
27. Haus EL, Smolensky MH. Shift work and cancer risk: potential mechanistic roles of circadian disruption, light at night, and sleep deprivation. Sleep medicine reviews. 2013; 17:273-284.
28. Reppert SM, Weaver DR. Coordination of circadian timing in mammals. Nature. 2002; 418:935-941.
29. Antle MC, Silver R. Orchestrating time: arrangements of the brain circadian clock. Trends in neurosciences. 2005; 28:145-151.
30. Abrahamson EE, Moore RY. Suprachiasmatic nucleus in the mouse: retinal innervation, intrinsic organization and efferent projections. Brain research. 2001; 916:172-191.
31. Welsh DK, Takahashi JS, Kay SA. Suprachiasmatic nucleus: cell autonomy and network properties. Annual review of physiology. 2010; 72:551-577.
32. Butler MP, Silver R. Basis of robustness and resilience in the suprachiasmatic nucleus: individual neurons form nodes in circuits that cycle daily. Journal of biological rhythms. 2009; 24:340-352.
33. Silver R, Romero MT, Besmer HR, Leak R, Nunez JM, LeSauter J. Calbindin-D28K cells in the hamster SCN express light-induced Fos. Neuroreport. 1996; 7:1224-1228.
34. Monsees GM, Kraft P, Hankinson SE, Hunter DJ, Schernhammer ES. Circadian genes and breast susceptibility in rotating shift workers. International journal of cancer Journal international du cancer. 2012; 131:2547-2552.
35. Folkard S. Do permanent night workers show circadian adjustment? A review based on the endogenous melatonin rhythm. Chronobiology international. 2008; 25:215-224.
36. Haus E, Smolensky M. Biological clocks and shift work: circadian dysregulation and potential long-term effects. Cancer causes & control: CCC. 2006; 17:489-500.
37. Korkmaz A, Topal T, Tan DX, Reiter RJ. Role of melatonin in metabolic regulation. Reviews in endocrine & metabolic disorders. 2009; 10:261-270.
38. Arendt J. Melatonin and human rhythms. Chronobiology international. 2006; 23:21-37.
39. Blask DE. Melatonin, sleep disturbance and cancer risk. Sleep medicine reviews. 2009; 13:257-264.
40. Dauchy RT, Xiang S, Mao L, Brimer S, Wren MA, Yuan L, Anbalagan M, Hauch A, Frasch T, Rowan BG, Blask DE, Hill SM. Circadian and melatonin disruption by exposure to light at night drives intrinsic resistance to tamoxifen therapy in breast cancer. Cancer research. 2014; 74:4099-4110.
41. Kothari A, Borges A, Ingle A, Kothari L. Combination of melatonin and tamoxifen as a chemoprophylaxis against N-nitroso-N-methylurea-induced rat mammary tumors. Cancer letters. 1997; 111:59-66.
42. Wilson ST, Blask DE, Lemus-Wilson AM. Melatonin augments the sensitivity of MCF-7 human breast cancer cells to tamoxifen in vitro. The Journal of clinical endocrinology and metabolism. 1992; 75:669-670.
43. Levi F. Chronotherapeutics: the relevance of timing in cancer therapy. Cancer causes & control: CCC. 2006; 17:611-621.
44. Blumenthal RD, Waskewich C, Goldenberg DM, Lew W, Flefleh C, Burton J. Chronotherapy and chronotoxicity of the cyclooxygenase-2 inhibitor, celecoxib, in athymic mice bearing human breast cancer xenografts. Clinical cancer research: an official journal of the American Association for Cancer Research. 2001; 7:3178-3185.
45. Depres-Brummer P, Berthault-Cvitkovic F, Levi F, Brienza S, Vannetzel JM, Jasmin C, Misset JL. Circadian rhythm-modulated (CRM) chemotherapy of metastatic breast cancer with mitoxantrone, 5-fluorouracil, and folinic acid: preliminary results of a phase I trial. The Journal of infusional chemotherapy. 1995; 5:144-147.
46. Reiter RJ. Mechanisms of cancer inhibition by melatonin. Journal of pineal research. 2004; 37:213-214.
47. Blask DE, Dauchy RT, Sauer LA, Krause JA, Brainard GC. Growth and fatty acid metabolism of human breast cancer (MCF-7) xenografts in nude rats: impact of constant light-induced nocturnal melatonin suppression. Breast research and treatment. 2003; 79:313-320.
48. Cos S, Mediavilla D, Martinez-Campa C, Gonzalez A, Alonso-Gonzalez C, Sanchez-Barcelo EJ. Exposure to light-at-night increases the growth of DMBA-induced mammary adenocarcinomas in rats. Cancer letters. 2006; 235:266-271.
49. Sauer LA, Dauchy RT, Blask DE. Melatonin inhibits fatty acid transport in inguinal fat pads of hepatoma 7288CTC-bearing and normal Buffalo rats via receptor-mediated signal transduction. Life sciences. 2001; 68:2835-2844.
50. Benitez-King G, Huerto-Delgadillo L, Anton-Tay F. Binding of 3H-melatonin to calmodulin. Life sciences. 1993; 53:201-207.
51. Coticchia CM, Revankar CM, Deb TB, Dickson RB, Johnson MD. Calmodulin modulates Akt activity in human breast cancer cell lines. Breast cancer research and treatment. 2009; 115:545-560.
52. Soto-Vega E, Meza I, Ramirez-Rodriguez G, Benitez-KingG. Melatonin stimulates calmodulin phosphorylation by protein kinase C. Journal of pineal research. 2004; 37:98-106.
53. Storch KF, Lipan O, Leykin I, Viswanathan N, Davis FC, Wong WH, Weitz CJ. Extensive and divergent circadian gene expression in liver and heart. Nature. 2002; 417:78-83.
54. Albrecht U, Ripperger J.A. Clock Genes. Encyclopedia of Neuroscience: Springer Berlin Heidelberg. 759-762.
55. Ko CH, Takahashi JS. Molecular components of the mammalian circadian clock. Human molecular genetics. 2006; 15 Spec No 2:R271-277.
56. Eide EJ, Woolf MF, Kang H, Woolf P, Hurst W, Camacho F, Vielhaber EL, Giovanni A, Virshup DM. Control of mammalian circadian rhythm by CKIepsilon-regulated proteasome-mediated PER2 degradation. Molecular and cellular biology. 2005; 25:2795-2807.
57. Lowrey PL, Shimomura K, Antoch MP, Yamazaki S, Zemenides PD, Ralph MR, Menaker M, Takahashi JS. Positional syntenic cloning and functional characterization of the mammalian circadian mutation tau. Science. 2000; 288:483-492.
58. Nakamura W, Yamazaki S, Takasu NN, Mishima K, Block GD. Differential response of Period 1 expression within the suprachiasmatic nucleus. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2005; 25:5481-5487.
59. Gery S, Komatsu N, Baldjyan L, Yu A, Koo D, Koeffler HP. The circadian gene per1 plays an important role in cell growth and DNA damage control in human cancer cells. Molecular cell. 2006; 22:375-382.
60. Gery S, Virk RK, Chumakov K, Yu A, Koeffler HP. The clock gene Per2 links the circadian system to the estrogen receptor. Oncogene. 2007; 26:7916-7920.
61. Parl FF, Dawling S, Roodi N, Crooke PS. Estrogen metabolism and breast cancer: a risk model. Annals of the New York Academy of Sciences. 2009; 1155:68-75.
62. Xiao L, Chang AK, Zang MX, Bi H, Li S, Wang M, Xing X, Wu H. Induction of the CLOCK gene by E2-ERalpha signaling promotes the proliferation of breast cancer cells. PloS one. 2014; 9:e95878.
63. Hoffman AE, Yi CH, Zheng T, Stevens RG, Leaderer D, Zhang Y, Holford TR, Hansen J, Paulson J, Zhu Y. CLOCK in breast tumorigenesis: genetic, epigenetic, and transcriptional profiling analyses. Cancer research. 2010; 70:1459-1468.
64. Jung CH, Kim EM, Park JK, Hwang SG, Moon SK, Kim WJ, Um HD. Bmal1 suppresses cancer cell invasion by blocking the phosphoinositide 3-kinase-Akt-MMP-2 signaling pathway. Oncology reports. 2013; 29:2109-2113.
65. Zeng ZL, Wu MW, Sun J, Sun YL, Cai YC, Huang YJ, Xian LJ. Effects of the biological clock gene Bmal1 on tumour growth and anti-cancer drug activity. Journal of biochemistry. 2010; 148:319-326.
66. Wang C, Fan S, Li Z, Fu M, Rao M, Ma Y, Lisanti MP, Albanese C, Katzenellenbogen BS, Kushner PJ, Weber B, Rosen EM, Pestell RG. Cyclin D1 antagonizes BRCA1 repression of estrogen receptor alpha activity. Cancer research. 2005; 65:6557-6567.
67. Fu L, Pelicano H, Liu J, Huang P, Lee C. The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo. Cell. 2002; 111:41-50.
68. Chen-Goodspeed M, Lee CC. Tumor suppression and circadian function. Journal of biological rhythms. 2007; 22:291-298.
69. Matsuo T, Yamaguchi S, Mitsui S, Emi A, Shimoda F, Okamura H. Control mechanism of the circadian clock for timing of cell division in vivo. Science. 2003; 302:255-259.
70. Vriend LE, De Witt Hamer PC, Van Noorden CJ, Wurdinger T. WEE1 inhibition and genomic instability in cancer. Biochimica et biophysica acta. 2013; 1836:227-235.
71. Parker LL, Piwnica-Worms H. Inactivation of the p34cdc2-cyclin B complex by the human WEE1 tyrosine kinase. Science. 1992; 257:1955-1957.
72. Hoffman AE, Zheng T, Yi CH, Stevens RG, Ba Y, Zhang Y, Leaderer D, Holford T, Hansen J, Zhu Y. The core circadian gene Cryptochrome 2 influences breast cancer risk, possibly by mediating hormone signaling. Cancer prevention research. 2010; 3:539-548.
73. Klose RJ, Bird AP. Genomic DNA methylation: the mark and its mediators. Trends in biochemical sciences. 2006; 31:89-97.
74. Liang G, Chan MF, Tomigahara Y, Tsai YC, Gonzales FA, Li E, Laird PW, Jones PA. Cooperativity between DNA methyltransferases in the maintenance methylation of repetitive elements. Molecular and cellular biology. 2002; 22:480-491.
75. Goll MG, Bestor TH. Eukaryotic cytosine methyltransferases. Annual review of biochemistry. 2005; 74:481-514.
76. Hata K, Okano M, Lei H, Li E. Dnmt3L cooperates with the Dnmt3 family of de novo DNA methyltransferases to establish maternal imprints in mice. Development (Cambridge, England). 2002; 129:1983-1993.
77. Weber M, Schubeler D. Genomic patterns of DNA methylation: targets and function of an epigenetic mark. Current opinion in cell biology. 2007; 19:273-280.
78. Jovanovic J, Ronneberg JA, Tost J, Kristensen V. The epigenetics of breast cancer. Molecular oncology. 2010; 4:242-254.
79. De Smet C, Loriot A, Boon T. Promoter-dependent mechanism leading to selective hypomethylation within the 5′ region of gene MAGE-A1 in tumor cells. Molecular and cellular biology. 2004; 24:4781-4790.
80. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB, Sidransky D. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nature medicine. 1995; 1:686-692.
81. Jiang G, Plo I, Wang T, Rahman M, Cho JH, Yang E, Lopez BS, Xia F. BRCA1-Ku80 protein interaction enhances end-joining fidelity of chromosomal double-strand breaks in the G1 phase of the cell cycle. The Journal of biological chemistry. 2013; 288:8966-8976.
82. Lieberman HB, Bernstock JD, Broustas CG, Hopkins KM, Leloup C, Zhu A. The role of RAD9 in tumorigenesis. Journal of molecular cell biology. 2011; 3:39-43.
83. Veeck J, Wild PJ, Fuchs T, Schuffler PJ, Hartmann A, Knuchel R, Dahl E. Prognostic relevance of Wnt-inhibitory factor-1 (WIF1) and Dickkopf-3 (DKK3) promoter methylation in human breast cancer. BMC cancer. 2009; 9:217.
84. Lamb R, Ablett MP, Spence K, Landberg G, Sims AH, Clarke RB. Wnt pathway activity in breast cancer sub-types and stem-like cells. PloS one. 2013; 8:e67811.
85. Chen H, Chung S, Sukumar S. HOXA5-induced apoptosis in breast cancer cells is mediated by caspases 2 and 8. Molecular and cellular biology. 2004; 24:924-935.
86. Salminen A, Kauppinen A, Hiltunen M, Kaarniranta K. Epigenetic regulation of ASC/TMS1 expression: potential role in apoptosis and inflammasome function. Cellular and molecular life sciences: CMLS. 2014; 71:1855-1864.
87. Euhus DM, Bu D, Milchgrub S, Xie XJ, Bian A, Leitch AM, Lewis CM. DNA methylation in benign breast epithelium in relation to age and breast cancer risk. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research,cosponsored by the American Society of Preventive Oncology. 2008; 17:1051-1059.
88. Ferguson AT, Lapidus RG, Baylin SB, Davidson NE. Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression. Cancer research. 1995; 55:2279-2283.
89. Lapidus RG, Ferguson AT, Ottaviano YL, Parl FF, Smith HS, Weitzman SA, Baylin SB, Issa JP, Davidson NE. Methylation of estrogen and progesterone receptor gene 5′ CpG islands correlates with lack of estrogen and progesterone receptor gene expression in breast tumors. Clinical cancer research: an official journal of the American Association for Cancer Research. 1996; 2:805-810.
90. Weigel RJ, deConinck EC. Transcriptional control of estrogen receptor in estrogen receptor-negative breast carcinoma. Cancer research. 1993; 53:3472-3474.
91. Izadi P, Noruzinia M, Karimipoor M, Karbassian MH, Akbari MT. Promoter hypermethylation of estrogen receptor alpha gene is correlated to estrogen receptor negativity in Iranian patients with sporadic breast cancer. Cell journal. 2012; 14:102-109.
92. Feng W, Shen L, Wen S, Rosen DG, Jelinek J, Hu X, Huan S, Huang M, Liu J, Sahin AA, Hunt KK, Bast RC Jr, Shen Y, Issa JP, Yu Y. Correlation between CpG methylation profiles and hormone receptor status in breast cancers. Breast cancer research: BCR. 2007; 9:R57.
93. Ehrlich M. DNA hypomethylation in cancer cells. Epigenomics. 2009; 1:239-259.
94. Feinberg AP, Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature. 1983; 301:89-92.
95. Brena RM, Costello JF. Genome-epigenome interactions in cancer. Human molecular genetics. 2007; 16 Spec No 1:R96-105.
96. Hormozdiari F, Alkan C, Ventura M, Hajirasouliha I, Malig M, Hach F, Yorukoglu D, Dao P, Bakhshi M, Sahinalp SC, Eichler EE. Alu repeat discovery and characterization within human genomes. Genome research. 2011; 21:840-849.
97. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, Devon K, Dewar K, Doyle M, FitzHugh W, Funke R, Gage D, Harris K, Heaford A, Howland J, Kann L, et al. Initial sequencing and analysis of the human genome. Nature. 2001; 409:860-921.
98. Park SY, Seo AN, Jung HY, Gwak JM, Jung N, Cho NY, Kang GH. Alu and LINE-1 hypomethylation is associated with HER2 enriched subtype of breast cancer. PloS one. 2014; 9:e100429.
99. Kitkumthorn N, Mutirangura A. Long interspersed nuclear element-1 hypomethylation in cancer: biology and clinical applications. Clinical epigenetics. 2011; 2:315-330.
100. Lister R, Pelizzola M, Dowen RH, Hawkins RD, Hon G, Tonti-Filippini J, Nery JR, Lee L, Ye Z, Ngo QM, Edsall L, Antosiewicz-Bourget J, Stewart R, Ruotti V, Millar AH, Thomson JA, et al. Human DNA methylomes at base resolution show widespread epigenomic differences. Nature. 2009; 462:315-322.
101. Hon GC, Hawkins RD, Caballero OL, Lo C, Lister R, Pelizzola M, Valsesia A, Ye Z, Kuan S, Edsall LE, Camargo AA, Stevenson BJ, Ecker JR, Bafna V, StrausbergRL, SimpsonAJ, et al. Global DNA hypomethylation coupled to repressive chromatin domain formation and gene silencing in breast cancer. Genome research. 2012; 22:246-258.
102. Annecke K, Schmitt M, Euler U, Zerm M, Paepke D, Paepke S, von Minckwitz G, Thomssen C, Harbeck N. uPA and PAI-1 in breast cancer: review of their clinical utility and current validation in the prospective NNBC-3 trial. Advances in clinical chemistry. 2008; 45:31-45.
103. Pakneshan P, Tetu B, Rabbani SA. Demethylation of urokinase promoter as a prognostic marker in patients with breast carcinoma. Clinical cancer research: an official journal of the American Association for Cancer Research. 2004; 10:3035-3041.
104. Novak P, Jensen T, Oshiro MM, Watts GS, Kim CJ, Futscher BW. Agglomerative epigenetic aberrations are a common event in human breast cancer. Cancer research. 2008; 68:8616-8625.
105. Shann YJ, Cheng C, Chiao CH, Chen DT, Li PH, Hsu MT. Genome-wide mapping and characterization of hypomethylated sites in human tissues and breast cancer cell lines. Genome research. 2008; 18:791-801.
106. Joska TM, Zaman R, Belden WJ. Regulated DNA methylation and the circadian clock: implications in cancer. Biology. 2014; 3:560-577.
107. Azzi A, Dallmann R, Casserly A, Rehrauer H, Patrignani A, Maier B, Kramer A, Brown SA. Circadian behavior is light-reprogrammed by plastic DNA methylation. Nature neuroscience. 2014; 17:377-382.
108. Chen ST, Choo KB, Hou MF, Yeh KT, Kuo SJ, Chang JG. Deregulated expression of the PER1, PER2 and PER3 genes in breast cancers. Carcinogenesis. 2005; 26:1241-1246.
109. Tsutsui S, Ohno S, Murakami S, Hachitanda Y, Oda S. Prognostic value of c-erbB2 expression in breast cancer. Journal of surgical oncology. 2002; 79:216-223.
110. Hwang HW, Mendell JT. MicroRNAs in cell proliferation, cell death, and tumorigenesis. British journal of cancer. 2006; 94:776-780.
111. Liu CG, Calin GA, Volinia S, Croce CM. MicroRNA expression profiling using microarrays. Nature protocols. 2008; 3:563-578.
112. Liu CG, Spizzo R, Calin GA, Croce CM. Expression profiling of microRNA using oligo DNA arrays. Methods (San Diego, Calif). 2008; 44:22-30.
113. Rodriguez A, Griffiths-Jones S, Ashurst JL, Bradley A. Identification of mammalian microRNA host genes and transcription units. Genome research. 2004; 14:1902-1910.
114. Fujita S, Iba H. Putative promoter regions of miRNA genes involved in evolutionarily conserved regulatory systems among vertebrates. Bioinformatics (Oxford, England). 2008; 24:303-308.
115. Griffiths-Jones S, Saini HK, van Dongen S, Enright AJ. miRBase: tools for microRNA genomics. Nucleic acids research. 2008; 36:D154-158.
116. Koturbash I, Zemp FJ, Pogribny I, Kovalchuk O. Small molecules with big effects: the role of the microRNAome in cancer and carcinogenesis. Mutation research. 2011; 722:94-105.
117. Ranganna K, Mathew OP, Milton SG, Hayes BE. MicroRNAome of Vascular Smooth Muscle Cells: Potential for MicroRNA-Based Vascular Therapies. 2013.
118. Chen CZ, Li L, Lodish HF, Bartel DP. MicroRNAs modulate hematopoietic lineage differentiation. Science. 2004; 303:83-86.
119. Lee Y, Kim M, Han J, Yeom KH, Lee S, Baek SH, Kim VN. MicroRNA genes are transcribed by RNA polymerase II. The EMBO journal. 2004; 23:4051-4060.
120. Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nature reviews Genetics. 2010; 11:597-610.
121. Lee Y, Jeon K, Lee JT, Kim S, Kim VN. MicroRNA maturation: stepwise processing and subcellular localization. The EMBO journal. 2002; 21:4663-4670.
122. Lee Y, Ahn C, Han J, Choi H, Kim J, Yim J, Lee J, Provost P, Radmark O, Kim S, Kim VN. The nuclear RNase III Drosha initiates microRNA processing. Nature. 2003; 425:415-419.
123. Hutvagner G, Zamore PD. RNAi: nature abhors a double-strand. Current opinion in genetics & development. 2002; 12:225-232.
124. Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W, Tuschl T. Identification of tissue-specific microRNAs from mouse. Current biology: CB. 2002; 12:735-739.
125. Lim LP, Lau NC, Weinstein EG, Abdelhakim A, Yekta S, Rhoades MW, Burge CB, Bartel DP. The microRNAs of Caenorhabditis elegans. Genes & development. 2003; 17:991-1008.
126. Khvorova A, Reynolds A, Jayasena SD. Functional siRNAs and miRNAs exhibit strand bias. Cell. 2003; 115:209-216.
127. Liu J, Valencia-Sanchez MA, Hannon GJ, Parker R. MicroRNA-dependent localization of targeted mRNAs to mammalian P-bodies. Nature cell biology. 2005; 7:719-723.
128. Thomson DW, Bracken CP, Goodall GJ. Experimental strategies for microRNA target identification. Nucleic acids research. 2011; 39:6845-6853.
129. Chen Y, Wang J, Wang X, Liu X, Li H, Lv Q, Zhu J, Wei B, Tang Y. STAT3, a Poor Survival Predicator, Is Associated with Lymph Node Metastasis from Breast Cancer. Journal of breast cancer. 2013; 16:40-49.
130. Frankel LB, Christoffersen NR, Jacobsen A, Lindow M, Krogh A, Lund AH. Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. The Journal of biological chemistry. 2008; 283:1026-1033.
131. Gong C, Yao Y, Wang Y, Liu B, Wu W, Chen J, Su F, Yao H, Song E. Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer. The Journal of biological chemistry. 2011; 286:19127-19137.
132. Lu Y, Lin YZ, LaPushin R, Cuevas B, Fang X, Yu SX, Davies MA, Khan H, Furui T, Mao M, Zinner R, Hung MC, Steck P, Siminovitch K, Mills GB. The PTEN/MMAC1/TEP tumor suppressor gene decreases cell growth and induces apoptosis and anoikis in breast cancer cells. Oncogene. 1999; 18:7034-7045.
133. Weng LP, Brown JL, Eng C. PTEN coordinates G(1) arrest by down-regulating cyclin D1 via its protein phosphatase activity and up-regulating p27 via its lipid activity in a breast cancer model. Human molecular genetics. 2001; 10:599-604.
134. Goke R, Barth P, Schmidt A, Samans B, Lankat-ButtgereitB. Programmed cell death protein 4 suppresses CDK1/cdc2 via induction of p21(Waf1/Cip1). American journal of physiology Cell physiology. 2004; 287:C1541-1546.
135. Yan LX, Wu QN, Zhang Y, Li YY, Liao DZ, Hou JH, Fu J, Zeng MS, Yun JP, Wu QL, Zeng YX, Shao JY. Knockdown of miR-21 in human breast cancer cell lines inhibits proliferation, in vitro migration and in vivo tumor growth. Breast cancer research: BCR. 2011; 13:R2.
136. Stinson S, Lackner MR, Adai AT, Yu N, Kim HJ, O'Brien C, Spoerke J, Jhunjhunwala S, Boyd Z, Januario T, Newman RJ, Yue P, Bourgon R, Modrusan Z, Stern HM, Warming S, et al. TRPS1 targeting by miR-221/222 promotes the epithelial-to-mesenchymal transition in breast cancer. Science signaling. 2011; 4:ra41.
137. Zhao JJ, Lin J, Yang H, Kong W, He L, Ma X, Coppola D, Cheng JQ. MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. The Journal of biological chemistry. 2008; 283:31079-31086.
138. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. The Journal of clinical investigation. 2009; 119:1420-1428.
139. Hu Y, Zhu Q, Tang L. MiR-99a antitumor activity in human breast cancer cells through targeting of mTOR expression. PloS one. 2014; 9:e92099.
140. Leis O, Eguiara A, Lopez-Arribillaga E, Alberdi MJ, Hernandez-Garcia S, Elorriaga K, Pandiella A, Rezola R, Martin AG. Sox2 expression in breast tumours and activation in breast cancer stem cells. Oncogene. 2012; 31:1354-1365.
141. Zhang Y, Eades G, Yao Y, Li Q, Zhou Q. Estrogen receptor alpha signaling regulates breast tumor-initiating cells by down-regulating miR-140 which targets the transcription factor SOX2. The Journal of biological chemistry. 2012; 287:41514-41522.
142. Yan X, Chen X, Liang H, Deng T, Chen W, Zhang S, Liu M, Gao X, Liu Y, Zhao C, Wang X, Wang N, Li J, Liu R, Zen K, Zhang CY, et al. miR-143 and miR-145 synergistically regulate ERBB3 to suppress cell proliferation and invasion in breast cancer. Molecular cancer. 2014; 13:220.
143. Sire C, Moreno AB, Garcia-Chapa M, Lopez-Moya JJ, San Segundo B. Diurnal oscillation in the accumulation of Arabidopsis microRNAs, miR167, miR168, miR171 and miR398. FEBS letters. 2009; 583:1039-1044.
144. Na YJ, Sung JH, Lee SC, Lee YJ, Choi YJ, Park WY, Shin HS, Kim JH. Comprehensive analysis of microRNA-mRNA co-expression in circadian rhythm. Experimental & molecular medicine. 2009; 41:638-647.
145. Nagel R, Clijsters L, Agami R. The miRNA-192/194 cluster regulates the Period gene family and the circadian clock. The FEBS journal. 2009; 276:5447-5455.
146. Cheng HY, Papp JW, Varlamova O, Dziema H, Russell B, Curfman JP, Nakazawa T, Shimizu K, Okamura H, Impey S, Obrietan K. microRNA modulation of circadian-clock period and entrainment. Neuron. 2007; 54:813-829.
147. Alvarez-Saavedra M, Antoun G, Yanagiya A, Oliva-Hernandez R, Cornejo-Palma D, Perez-Iratxeta C, Sonenberg N, Cheng HY. miRNA-132 orchestrates chromatin remodeling and translational control of the circadian clock. Human molecular genetics. 2011; 20:731-751.
148. Zhang ZG, Chen WX, Wu YH, Liang HF, Zhang BX. MiR-132 prohibits proliferation, invasion, migration, and metastasis in breast cancer by targeting HN1. Biochemical and biophysical research communications. 2014; 454:109-114.
149. Schwimmer H, Metzer A, Pilosof Y, Szyf M, Machnes ZM, Fares F, Harel O, Haim A. Light at night and melatonin have opposite effects on breast cancer tumors in mice assessed by growth rates and global DNA methylation. Chronobiology international. 2014; 31:144-150.
150. Zhu Y, Stevens RG, Hoffman AE, Tjonneland A, Vogel UB, Zheng T, Hansen J. Epigenetic impact of long-term shiftwork: pilot evidence from circadian genes and whole-genome methylation analysis. Chronobiology international. 2011; 28:852-861.
151. Jacobs DI, Hansen J, Fu A, Stevens RG, Tjonneland A, Vogel UB, Zheng T, Zhu Y. Methylation alterations at imprinted genes detected among long-term shiftworkers. Environmental and molecular mutagenesis. 2013; 54:141-146.
152. Morini M, Astigiano S, Gitton Y, Emionite L, Mirisola V, Levi G, Barbieri O. Mutually exclusive expression of DLX2 and DLX5/6 is associated with the metastatic potential of the human breast cancer cell line MDA-MB-231. BMC cancer. 2010; 10:649.
153. Sigal A, Rotter V. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer research. 2000; 60:6788-6793.
154. Shi F, Chen X, Fu A, Hansen J, Stevens R, Tjonneland A, Vogel UB, Zheng T, Zhu Y. Aberrant DNA methylation of miR-219 promoter in long-term night shiftworkers. Environmental and molecular mutagenesis. 2013; 54:406-413.
155. Liu K, Wang R. MicroRNA-mediated regulation in the mammalian circadian rhythm. Journal of theoretical biology. 2012; 304:103-110.
156. Liu R, Jacobs DI, Hansen J, Fu A, Stevens RG, Zhu Y. Aberrant methylation of miR-34b is associated with long-term shiftwork: a potential mechanism for increased breast cancer susceptibility. Cancer causes & control : CCC. 2015; 26:171-178.
157. Kim IS, Baek SH. Mouse models for breast cancer metastasis. Biochemical and biophysical research communications. 2010; 394:443-447.